AIDS-Related Lymphoma Treatment (PDQ®)–Health Professional Version

SECTIONS

Changes to This Summary (08/08/2018)

The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

Editorial changes were made to this summary.

General Information About AIDS-Related Lymphoma

Revised text of the Multicentric Castleman disease heading and stated that the plasmablastic type of multicentric Castleman disease is also associated with a coinfection of KSHV/HHV8 and HIV (cited Bower et al. as reference 19).

Added text to state that for a prospective cohort of 84 patients treated with rituximab for HIV and human herpes virus type 8 multicentric Castleman disease, the 5-year rate of relapse-free survival was 82%, and all patients responded again to rituximab at relapse (cited Pria et al. as reference 23 and level of evidence 3iiiDiii).

Treatment Option Overview for AIDS-Related Lymphoma

Revised text of first component of an optimal non-Hodgkin lymphoma treatment strategy to read highly active antiretroviral therapy (HAART).

Added text to state that an anecdotal report using HAART and high-dose methotrexate for patients with AIDS-related primary CNS lymphoma showed a median survival that had not been reached with a median follow-up of 27 months (cited Gupta et al. as reference 16).

This summary is written and maintained by the PDQ Adult Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ® - NCI's Comprehensive Cancer Database pages.

< Previous section
AIDS-Related Primary Central Nervous System Lymphoma

Next section >
About This PDQ Summary